Back
Speaker illustration

undefined undefined undefined

Presentations

Atrial fibrillation is associated with worse outcome in patients with wild-type transthyretin amyloid cardiomyopathy

Event: Heart Failure 2025

Topic: Epidemiology, Prognosis, Outcome

Session: From epidemiology to outcomes

Access
Like
Thumbnail

Tafamidis reduces the burden of atrial fibrillation in patients with wild-type transthyretin amyloid cardiomyopathy

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Amyloid and acute heart failure therapy advances

Access
Like
Thumbnail

Prognostic factors associated with survival in patients with wild-type transthyretin amyloid cardiomyopathy, treated with tafamidis

Event: Heart Failure 2024

Topic: Epidemiology, Prognosis, Outcome

Session: ePosters in chronic heart failure - epidemiology, prognosis, outcome 3

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources